Self-amplifying RNA-based CAR T cell therapy with enhanced duration and multi-genic logic functions

Area of Science:

• Immunotherapy
• Molecular Biology
• Oncology

Background:

• Chimeric antigen receptor T (CAR-T) cell therapy is a promising treatment for hematological malignancies.
• Current CAR-T manufacturing using viral vectors is expensive, time-consuming, and carries risks like insertional mutagenesis.
• Messenger RNA (mRNA) CAR T cells offer improved safety and speed but require frequent dosing due to short expression.

Purpose of the Study:

• To develop and evaluate a modified self-amplifying RNA (saRNA) platform for CAR T cell engineering.
• To assess the efficacy and durability of saRNA CAR T cells compared to mRNA CAR T cells.
• To explore the potential of saRNA for advanced CAR T cell designs.

Main Methods:

• Engineering CAR T cells using a modified self-amplifying RNA (saRNA) platform.
• Evaluating saRNA CAR T cell performance in an acute lymphoblastic leukemia (ALL) xenograft model.
• Assessing the co-expression capabilities of saRNA for advanced CAR systems.

Main Results:

• saRNA CAR T cells demonstrated prolonged CAR expression and enhanced durability of tumor control compared to mRNA CAR T cells.
• Superior tumor suppression and prolonged survival were observed in the ALL xenograft model using saRNA CAR T cells.
• The saRNA platform successfully enabled co-expression of multiple proteins for advanced CAR designs like logic-gated CAR T cells.

Conclusions:

• The modified saRNA platform offers a powerful and versatile approach for CAR T cell engineering.
• saRNA CAR T cells present a favorable safety, efficacy, and accessibility profile for cancer therapy.
• This technology has the potential to advance CAR T cell therapy for hematological malignancies and beyond.